This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| Vistry Group PLC | 1,430.0 | 8.5% |
| WPP PLC | 746.6 | 5.6% |
| Entain PLC | 647.2 | 5.1% |
| Whitbread PLC | 3,008.0 | 3.7% |
| SSE PLC | 1,970.0 | 3.0% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| Associated British Foods PLC | 2289.0 | -8.5% |
| Admiral Group PLC | 2814.0 | -4.0% |
| Spirax Group PLC | 7295.0 | -2.8% |
| Astrazeneca PLC | 12688.7 | -2.7% |
| Smith (Ds) PLC | 452.2 | -2.6% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 8,242 | -0.3% | 10.8% |
| DOW JONES INDUS. AVG | 40,756 | -0.5% | 17.7% |
| DAX INDEX | 18,577 | -0.1% | 17.8% |
| NIKKEI 225 | 36,657 | -1.1% | 10.3% |
| S&P/ASX 200 INDEX | 7,982 | 0.4% | 10.0% |
| Commodities | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 69.15 | -0.07% |
| Brent Crude (ICE) | USD/bbl. | 72.87 | 0.23% |
| Gold Spot | USD/t oz. | 2,517 | 0.8% |
| Copper (Comex) | USd/lb. | 414 | 1.4% |
Click graph to enlarge
The UK 100 called to open -11 points at 8,231. The UK 100 looks set to open moderately lower this morning as investors look ahead to today’s non-farm payroll announcement.
Stateside yesterday saw the S&P dipped 0.3% to end at 5,503.41, while the Dow Jones lost 219.22 points, or 0.54%, to settle at 40,755.75. The Nasdaq gained 0.25% to finish at 17,127.66, after rising as much as 1.2% earlier in the session.
Asian shares traded mixed Friday ahead of a highly anticipated U.S. jobs report that’s expected to influence how the U.S. Federal Reserve will move on interest rates.
Japan’s benchmark Nikkei was little changed in morning trading, gaining less than 0.1% to 36,657.79. Australia’s markets rose 0.6% to 7,998.00, while South Korea’s Kospi slipped 1.8% to 2,529.31. The Shanghai Composite gained 0.3% to 2,797.15. Trading was halted in Hong Kong because of an approaching typhoon.
Berkeley Group today announced trading has been stable over the first four months of the year and are on target to achieve pre-tax earnings guidance for the full year ending 30 April 2025 of £525 million, 90% of which is already secured through exchanged sales contracts. Pre-tax profits for the year are expected to be weighted towards the first half, similarly to last year, and operating margin will therefore be slightly ahead of long-term range (17.5% to 19.5%) for this period. Net cash at 31 October 2024 will be around £450 million (30 April 2024: £532 million) following shareholder returns of £229 million in the first half, including a £184 million proposed special dividend that is subject to approval by shareholders at today’s AGM.
GSK today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).
No New broker comments
UK
Berkeley Group
Darktrace
Hilton Food Group
Playtech
US
None
UK
C&C Group*
Computacenter
US
Oracle
German Industrial Production
German Trade Balance
EU Employment Change
EU Gross Domestic Product
US Average Hourly Earnings
US Labor Force Participation Rate
US Nonfarm Payrolls
US Unemployment Rate
UK 100 companies going ex-dividend on 12th September 2024:
Endeavour Mining
Intertek Group
M&G
UK 250 companies going ex-dividend on 12th September 2024:
Baltic Classifieds Group
Goodwin
Grafton Group
Direct Line Insurance Group
Alpha Group International
International Public Partnerships
Apax Global Alpha
Bakkavor Group
SDCL Energy Efficiency Income Trust
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.